Riluzole’s role in treatment of spinal cord injuries – overview of studies on animals and humans
DOI:
https://doi.org/10.12775/JEHS.2025.80.60023Keywords
Riluzole, Spinal Cord Injury (SCI), GlutamateAbstract
Injuries in the spinal cord are responsible for disabling a great number of people each year. The primary and secondary damage varies in pathomechanisms, the latter one being heavily associated with excitotoxicity caused by excess extracellular glutamate. Riluzole, a drug used in amyotrophic lateral sclerosis, lowers the amount of released glutamate, thus making it a possible candidate for treatment in spinal cord injuries. Several studies have been performed on animals and humans, although their results do not always align. In controlled environments, when injuries to the neural tissue in the spinal cord are mechanical or ischemic, the drug’s usage shows promising effects in treated rats. Tests on humans are much harder to conduct and so the research has focused on already ill individuals. Their conditions vary, however, and not all of the people could recover, even to a small degree. Further studies need to be performed in order to qualify riluzole as a remedium to injuries of the spinal cord.
References
1. Smuder, A. J., Gonzalez-Rothi, E. J., Kwon, O. S., Morton, A. B., Sollanek, K. J., Powers, S. K., & Fuller, D. D. (2016). Cervical spinal cord injury exacerbates ventilator-induced diaphragm dysfunction. Journal of Applied Physiology, 120(2), 166–177.
2. Rouanet, C., Reges, D., Rocha, E., Gagliardi, V., & Silva, G. S. (2017). Traumatic spinal cord injury: current concepts and treatment update. Arquivos de Neuro-Psiquiatria, 75(6), 387–393.
3. Giannini, M. J., Bergmark, B., Kreshover, S., Elias, E., Plummer, C., & O’Keefe, E. (2010). Understanding suicide and disability through three major disabling conditions: Intellectual disability, spinal cord injury, and multiple sclerosis. Disability and Health Journal, 3(2), 74–78.
4. Eli, I., Lerner, D. P., & Ghogawala, Z. (2021). Acute Traumatic Spinal Cord Injury. Neurologic Clinics, 39(2), 471–488
5. McDonald, J. W., & Sadowsky, C. (2002). Spinal-cord injury. The Lancet, 359(9304), 417–425
6. Quadri, S. A., Farooqui, M., Ikram, A., Zafar, A., Khan, M. A., Suriya, S. S., … Mortazavi, M. M. (2018). Recent update on basic mechanisms of spinal cord injury. Neurosurgical Review.
7. Roberts, T. T., Leonard, G. R., & Cepela, D. J. (2016). Classifications In Brief: American Spinal Injury Association (ASIA) Impairment Scale. Clinical Orthopaedics and Related Research®, 475(5), 1499–1504.
8. Anjum, A., Yazid, M. D., Fauzi Daud, M., Idris, J., Ng, A. M. H., Selvi Naicker, A., … Lokanathan, Y. (2020). Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms. International Journal of Molecular Sciences, 21(20), 7533.
9. Ahuja, C. S., Nori, S., Tetreault, L., Wilson, J., Kwon, B., Harrop, J., … Fehlings, M. G. (2017). Traumatic Spinal Cord Injury—Repair and Regeneration. Neurosurgery, 80(3S), S9–S22.
10. Liu, D., Xu, G.-Y., Pan, E., & McAdoo, D. J. (1999). Neurotoxicity of glutamate at the concentration released upon spinal cord injury. Neuroscience, 93(4), 1383–1389.
11. Ahuja, C. S., Nori, S., Tetreault, L., Wilson, J., Kwon, B., Harrop, J., … Fehlings, M. G. (2017). Traumatic Spinal Cord Injury—Repair and Regeneration. Neurosurgery, 80(3S), S9–S22.
12. Lau, A., & Tymianski, M. (2010). Glutamate receptors, neurotoxicity and neurodegeneration. Pflügers Archiv - European Journal of Physiology, 460(2), 525–542.
13. Beattie, M. S., Hermann, G. E., Rogers, R. C., & Bresnahan, J. C. (2002). Chapter 4 Cell death in models of spinal cord injury. Spinal Cord Trauma: Regeneration, Neural Repair and Functional Recovery, 37–47.
14. Fan, B., Wei, Z., Yao, X., Shi, G., Cheng, X., Zhou, X., … Feng, S. (2018). Microenvironment Imbalance of Spinal Cord Injury. Cell Transplantation, 27(6), 853–866.
15. Chow, D. S. L., Teng, Y., Toups, E. G., Aarabi, B., Harrop, J. S., Shaffrey, C. I., … Grossman, R. G. (2012). Pharmacology of riluzole in acute spinal cord injury. Journal of Neurosurgery: Spine, 17(Suppl1), 129–140.
16. Cifra, A., Mazzone, G. L., & Nistri, A. (2012). Riluzole. The Neuroscientist, 19(2), 137–144.
17. Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010). Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis. Current Medicinal Chemistry, 17(18), 1942–1959. doi:10.2174/092986710791163939
18. Nagoshi, N., Nakashima, H., & Fehlings, M. (2015). Riluzole as a Neuroprotective Drug for Spinal Cord Injury: From Bench to Bedside. Molecules, 20(5), 7775–7789.
19. Sámano, C., & Nistri, A. (2017). Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone. Neurochemical Research.
20. Doble, A. (1996). The pharmacology and mechanism of action of riluzole. Neurology, 47(Issue 6, Supplement 4), 233S–241S.
21. Azbill, R. ., Mu, X., & Springer, J. . (2000). Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Research, 871(2), 175–180.
22. Wilson, J. R., & Fehlings, M. G. (2014). Riluzole for Acute Traumatic Spinal Cord Injury: A Promising Neuroprotective Treatment Strategy. World Neurosurgery, 81(5-6), 825–829.
23. Jiang, K., Zhuang, Y., Yan, M., Chen, H., Ge, A.-Q., Sun, L., & Miao, B. (2016). Effects of riluzole on P2X7R expression in the spinal cord in rat model of neuropathic pain. Neuroscience Letters, 618, 127–133.
24. Wu, Y., Satkunendrarajah, K., & Fehlings, M. G. (2014). Riluzole improves outcome following ischemia–reperfusion injury to the spinal cord by preventing delayed paraplegia. Neuroscience, 265, 302–312.
25. Barros Filho, T. E. P. de, & Molina, A. E. I. S. (2008). Analysis of the sensitivity and reproducibility of the Basso, Beattie, Bresnahan (BBB) scale in wistar rats. Clinics, 63(1), 103–108.
26. Caglar, Y. S., Demirel, A., Dogan, I., Huseynov, R., Eroglu, U., Ozgural, O., … Al-Beyati, E. S. M. (2018). Effect of Riluzole on Spinal Cord Regeneration with Hemisection Method Before Injury. World Neurosurgery, 114, e247–e253.
27. Tran, A. P., Warren, P. M., & Silver, J. (2021). New insights into glial scar formation after spinal cord injury. Cell and Tissue Research.
28. Wu, Q., Zhang, Y., Zhang, Y., Zhang, W., Zhang, W., Liu, Y., … Chen, X. (2020). Riluzole improves functional recovery after acute spinal cord injury in rats and may be associated with changes in spinal microglia/macrophages polarization. Neuroscience Letters, 723, 134829.
29. Wang, Pin; Jiang, Lu L; Wang, Cunfu; Zhu, Zhengyu; Lai, Chao (2020). Neurofilament Protein as a Potential Biomarker of Axonal Degeneration in Experimental Autoimmune Encephalomyelitis. Neurology India 68(2):p 364-367
30. Soustelle, L., Antal, M. C., Lamy, J., Rousseau, F., Armspach, J.-P., & Loureiro de Sousa, P. (2019). Correlations of quantitative MRI metrics with myelin basic protein (MBP) staining in a murine model of demyelination. NMR in Biomedicine, e4116.
31. Wilson, J. R., Forgione, N., & Fehlings, M. G. (2012). Emerging therapies for acute traumatic spinal cord injury. Canadian Medical Association Journal, 185(6), 485–492.
32. Hachem, L. D., Ahuja, C. S., & Fehlings, M. G. (2017). Assessment and management of acute spinal cord injury: From point of injury to rehabilitation. The Journal of Spinal Cord Medicine, 40(6), 665–675
33. Schwartz, G., & Fehlings, M. G. (2002). Chapter 14 Secondary injury mechanisms of spinal cord trauma: a novel therapeutic approach for the management of secondary pathophysiology with the sodium channel blocker riluzole. Spinal Cord Trauma: Regeneration, Neural Repair and Functional Recovery, 177–190.
34. Grossman, R. G., Fehlings, M. G., Frankowski, R. F., Burau, K. D., Chow, D. S. L., Tator, C., … Wilson, J. R. (2014). A Prospective, Multicenter, Phase I Matched-Comparison Group Trial of Safety, Pharmacokinetics, and Preliminary Efficacy of Riluzole in Patients with Traumatic Spinal Cord Injury. Journal of Neurotrauma, 31(3), 239–255.
35. Killestein, J., Kalkers, N. F., & Polman, C. H. (2005). Glutamate inhibition in MS: The neuroprotective properties of riluzole. Journal of the Neurological Sciences, 233(1-2), 113–115.
36. Fehlings, M. G., Badhiwala, J. H., Ahn, H., Farhadi, H. F., Shaffrey, C. I., Nassr, A., … Kopjar, B. (2020). Safety and efficacy of riluzole in patients undergoing decompressive surgery for degenerative cervical myelopathy (CSM-Protect): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. The Lancet Neurology.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Wenancjusz Stołowski, Natalia Rulewska, Filip Grabowski, Jakub Siemko, Dagmara Neska, Dominika Prystacka-Szar, Justyna Stadler-Szajda, Adrianna Czyżnikiewicz, Magdalena Bujak, Magdalena Waśniowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 206
Number of citations: 0
